Literature DB >> 3041640

Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man.

N E Seymour1, F C Brunicardi, R L Chaiken, H E Lebovitz, R E Chance, R L Gingerich, D Elahi, D K Andersen.   

Abstract

Pancreatic polypeptide (PP) deficiency has been associated with impaired hepatic sensitivity to insulin and pancreatogenic diabetes in chronic pancreatitis. Since pancreatic resection might also result in PP deficiency, hepatic responses to insulin infusion (0.25 mU/kg/min) were determined by the euglycemic glucose clamp technique in 10 patients who had previously undergone pancreatic resection for trauma and in eight healthy control subjects. Six resection patients (RES-PP) demonstrated deficient PP levels, with a mean increase of plasma immunoreactive PP of 20 +/- 7 pg/ml above basal rate after a test meal compared with 232 +/- 82 pg/ml in control subjects (p less than 0.01) and 353 +/- 133 pg/ml in four other patients undergoing resection with normal levels of immunoreactive PP (RES + PP) (p less than 0.03). Three identical insulin infusion studies were performed in each subject, the second of which was performed during the final 2 hours of an 8-hour infusion of bovine PP (2.0 pmol/kg/min). Whereas hepatic glucose production (HGP) in control subjects fell 74% +/- 4% from a basal rate of 2.0 +/- 0.1 mg/kg/min to a 60- to 120-minute value of 0.5 +/- 0.1 mg/kg/min during insulin infusion, HGP was suppressed only 58% +/- 5% in RES-PP subjects, from 1.9 +/- 0.1 to 0.8 +/- 0.1 mg/kg/min (p less than 0.05 vs controls). Intravenous infusion of PP corrected the hepatic resistance to insulin seen in the PP-deficient group. During PP infusion, HGP was suppressed 74% +/- 5% in RES-PP subjects, from 2.1 +/- 0.2 to 0.5 +/- 0.1 mg/kg/min (p less than 0.04 compared with initial study). PP infusion produced no significant change in glucose metabolism in control and RES + PP subjects. Overall glucose disposal rates were not altered by PP infusion in any group. These findings support a role of PP as a glucoregulatory hormone and suggest that PP deficiency may serve as a reversible pathophysiologic factor in the abnormal glucose metabolism seen after pancreatic resection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041640

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

Review 1.  Clinical uses of gut peptides.

Authors:  J Geoghegan; T N Pappas
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

Review 2.  Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Authors:  Phil A Hart; Melena D Bellin; Dana K Andersen; David Bradley; Zobeida Cruz-Monserrate; Christopher E Forsmark; Mark O Goodarzi; Aida Habtezion; Murray Korc; Yogish C Kudva; Stephen J Pandol; Dhiraj Yadav; Suresh T Chari
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-10-12

3.  Function and survival of intrasplenic islet autografts in dogs.

Authors:  M P van der Burg; O R Guicherit; J B Jansen; M Frölich; C B Lamers; H H Lemkes; J A Bruijn; H G Gooszen
Journal:  Diabetologia       Date:  1996-01       Impact factor: 10.122

4.  Human pancreatic polypeptide in a phospholipid-based micellar formulation.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

Review 5.  Elevated pancreatic polypeptide levels in pancreatic neuroendocrine tumors and diabetes mellitus: causation or association?

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Pancreas       Date:  2014-05       Impact factor: 3.327

6.  Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer.

Authors:  Phil A Hart; Dana K Andersen; Kieren J Mather; Alicia C Castonguay; Mandeep Bajaj; Melena D Bellin; David Bradley; Noemy Contreras; Aida Habtezion; Murray Korc; Yogish Kudva; Maxim S Petrov; David C Whitcomb; Dhiraj Yadav; Ying Yuan; Jo Ann S Rinaudo; Sudhir Srivastava; Jose Serrano; Mark O Goodarzi
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

7.  Pancreatic polypeptide administration enhances insulin sensitivity and reduces the insulin requirement of patients on insulin pump therapy.

Authors:  Atoosa Rabiee; Panagis Galiatsatos; Rocio Salas-Carrillo; Michael J Thompson; Dana K Andersen; Dariush Elahi
Journal:  J Diabetes Sci Technol       Date:  2011-11-01

8.  The influence of somatostatin on glucagon and pancreatic polypeptide secretion in the isolated perfused human pancreas.

Authors:  R Kleinman; R Gingerich; G Ohning; H Wong; K Olthoff; J Walsh; F C Brunicardi
Journal:  Int J Pancreatol       Date:  1995-08

9.  Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis.

Authors:  D K Andersen; C L Ruiz; C F Burant
Journal:  Ann Surg       Date:  1994-06       Impact factor: 12.969

Review 10.  Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection.

Authors:  Andrew E Becker; Yasmin G Hernandez; Harold Frucht; Aimee L Lucas
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.